STOCK TITAN
  1. Home
  2. Sec-filings
  3. GNPX
  4. [DEF 14A] Genprex, Inc. Definitive Proxy Statement

[DEF 14A] Genprex, Inc. Definitive Proxy Statement

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
DEF 14A
Rhea-AI Filing Summary
Analyzing...
Positive
  • None.
Negative
  • None.

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock GNPX logo
Genprex Inc

NASDAQ:GNPX

GNPX Rankings

#10833 Ranked by Market Cap
N/A Ranked by Dividends

GNPX Latest News

Jun 24, 2025
Genprex Collaborators Present Positive Preclinical Research on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions
Jun 23, 2025
Genprex Collaborators Present Research on Non-Viral Approach to Diabetes Gene Therapy Using Lipid Nanoparticle Delivery System at the 2025 American Diabetes Association 85th Scientific Sessions
Jun 3, 2025
Genprex to Participate at BIO 2025 International Convention
May 29, 2025
Genprex to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting
May 28, 2025
Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting

GNPX Latest SEC Filings

Jul 3, 2025
[PRE 14A] Genprex, Inc. Preliminary Proxy Statement
Jul 1, 2025
[Form 4] Genprex, Inc. Insider Trading Activity
Jul 1, 2025
[Form 4] Genprex, Inc. Insider Trading Activity
Jun 24, 2025
[8-K] Genprex, Inc. Reports Material Event
Jun 23, 2025
[8-K] Genprex, Inc. Reports Material Event

GNPX Stock Data

8.44M
28.95M
1.2%
3.42%
7.44%
Biotechnology
Pharmaceutical Preparations
Link
United States
AUSTIN